Roivant Sciences Ltd. $ROIV Position Lessened by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund trimmed its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report) by 10.4% during the third quarter, Holdings Channel.com reports. The institutional investor owned 142,909 shares of the company’s stock after selling 16,545 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Roivant Sciences were worth $5,226,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of ROIV. Wellington Management Group LLP increased its stake in shares of Roivant Sciences by 179.0% in the 2nd quarter. Wellington Management Group LLP now owns 2,687,870 shares of the company’s stock valued at $95,124,000 after acquiring an additional 1,724,588 shares in the last quarter. Maverick Capital Ltd. acquired a new position in shares of Roivant Sciences during the 1st quarter valued at $45,066,000. Assenagon Asset Management S.A. lifted its position in shares of Roivant Sciences by 18.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 8,362,952 shares of the company’s stock valued at $295,965,000 after acquiring an additional 1,286,464 shares during the period. Affinity Asset Advisors LLC lifted its position in shares of Roivant Sciences by 64.7% during the 1st quarter. Affinity Asset Advisors LLC now owns 2,800,000 shares of the company’s stock valued at $77,560,000 after acquiring an additional 1,100,000 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. bought a new position in Roivant Sciences during the third quarter worth $35,624,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Wall Street Analysts Forecast Growth

ROIV has been the subject of a number of research reports. HC Wainwright raised their price target on shares of Roivant Sciences from $47.00 to $48.00 and gave the stock a “buy” rating in a report on Tuesday, November 10th. Bank of America reaffirmed a “neutral” rating on shares of Roivant Sciences in a research note on Friday, July 31st. Guggenheim upped their price objective on shares of Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a report on Wednesday, September 9th. UBS Group set a $55.00 price objective on shares of Roivant Sciences in a research report on Wednesday, September 9th. Finally, Wolfe Research lowered Roivant Sciences from an “outperform” rating to a “peer perform” rating in a report on Monday, October 12th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Roivant Sciences presently has an average rating of “Moderate Buy” and an average target price of $46.64.

View Our Latest Report on ROIV

Trending Headlines about Roivant Sciences

Here are a few of the latest headlines about ROIV:

  • Positive Sentiment: HC Wainwright raised its price target to $48 and maintained a Buy rating. Other recent commentary has pointed to Roivant’s pipeline momentum and possible contributions from clinical progress and drug-launch revenue. HC Wainwright price-target report Pipeline momentum analysis
  • Neutral Sentiment: A separate article examines how trial outcomes and drug-launch revenue could affect ROIV, but the provided headline does not report new trial results or specific revenue figures. Trial and drug-launch analysis
  • Negative Sentiment: CEO Eric Venker sold 187,943 shares, reducing his stake by 18.81%; the sale was made under a pre-arranged Rule 10b5-1 plan. CFO Richard Pulik sold 125,000 shares on Nov. 10 and another 175,000 on Nov. 11, cutting his position by 44.08%. These substantial insider sales may create near-term pressure on the stock, although the CEO’s transaction was scheduled in advance. CEO SEC filing CFO insider-sales report

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, CFO Richard Pulik sold 175,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 11th. The stock was sold at an average price of $41.85, for a total transaction of $7,323,750.00. Following the completion of the sale, the chief financial officer directly owned 222,046 shares of the company’s stock, valued at approximately $9,292,625.10. The trade was a 44.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Eric Venker sold 200,000 shares of the stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $36.62, for a total value of $7,324,000.00. Following the completion of the sale, the chief executive officer directly owned 1,599,154 shares of the company’s stock, valued at approximately $58,561,019.48. This trade represents a 11.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 1,982,747 shares of company stock worth $74,398,784. Insiders own 8.80% of the company’s stock.

Roivant Sciences Price Performance

ROIV opened at $39.53 on Monday. Roivant Sciences Ltd. has a fifty-two week low of $19.96 and a fifty-two week high of $42.50. The firm has a market capitalization of $28.55 billion, a PE ratio of -62.75 and a beta of 1.23. The company’s 50-day moving average is $37.31 and its 200 day moving average is $32.25.

About Roivant Sciences

(Free Report)

Roivant Sciences is a biopharmaceutical company that develops medicines through a network of subsidiary companies, which it calls “Vants.” These businesses focus on advancing drug candidates in areas such as immunology, oncology, neuroscience and rare diseases. Founded in 2014, Roivant has built and supported subsidiaries to develop treatments, manage clinical programs and pursue partnerships. Its portfolio has included both internally developed candidates and medicines licensed from other companies.

Further Reading

Want to see what other hedge funds are holding ROIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report).

Institutional Ownership by Quarter for Roivant Sciences (NASDAQ:ROIV)

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.